



Matthias Ocker

Contact

Matthias Ocker

Publications (2)

Schneeweiss A, Lagkadinou E, Wilkinson G, Boix O, Thiele S, Rudolph M, Rentzsch C, Hurvitz S, Ma C, Tsimberidou A, Moulder S, Varga A, Jörger M, Hess D, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer–Lack of Association between Activating AKT Mutation and AKT Inhibition–Derived Efficacy. *Cancers (Basel)* 2019; 11

Schuler M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Schostak M, Park S, Cho B, Sayehli C, Navarro A, Soo R, Richly H, Cassier P, Tai D, Penel N, Nogova L, Jörger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. *Lancet Oncol* 2019

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch